Articles from Shenzhen Chipscreen Biosciences Co., Ltd.

The 2026 Congress of the European Society for Medical Oncology (ESMO) is being held in Madrid, Spain. Primary results from the global phase 3 trial of chidamide (HBI-8000, Epidaza®) plus nivolumab in advanced melanoma (Abstract LBA54) were presented by Nikhil I. Khushalani, MD, of Moffitt Cancer Center, in a Proffered Paper session. Additional exploratory studies of chidamide were also presented at the Congress.

Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”) (SSE: 688321) today announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with Chengdu Chipscreen Newway Biosciences Co., Ltd., has obtained IND approval from China’s National Medical Products Administration (NMPA). The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NW001 in patients with advanced tumors.

Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences” or the “Company”)(SSE: 688321) announced that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for CS43158 tablets, a new molecular entity for the treatment of acute myeloid leukemia (AML), discovered through the company’s AI-enabled Chemical Genomics Platform.